India, March 12 -- CervoMed Inc. (CRVO) is trading at $5.96, up 152.31 percent or $3.60, with no clear reason but a likely possibility that it is fueled by yesterday announced positive results from the extension phase of its Phase 2b clinical study of Neflamapimod in patients with dementia with Lewy bodies, which was announced yesterday.
The stock opened at $2.40 and has traded between $2.40 and $6.54 so far today, compared to a previous close of $2.36. Current volume has surged to 108.95 million shares, significantly exceeding the average volume of 225,556.
The stock's 52-week range is $1.80 to $26.38.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....